The third batch of drugs collection and opening of the standard in that, the market share of high stock varieties at a glance.

Pharmaceutical Network Market Analysis" The third batch of drug tape procurement, which has attracted much attention from the industry, will be officially opened in Shanghai on August 20, and the collection of basic pharmaceutical information is to be carried out on 52 drugs (a total of 86 standards).
according to incomplete statistics, the third batch of varieties involved in more than 100 production enterprises.
from the number of varieties involved in the enterprises, the original research and pharmaceutical companies Pfizer involved in the majority of varieties, followed by Mercado, Novartis and AstraZenico;
according to the Zhejiang Commercial Securities Research Institute collated part of the list of the market share of enterprises shows that Hengrui Pharmaceuticals, Fosun Pharma's bootha tablets, Hengrui Pharmaceuticals' tocosic tablets, Fosun Pharma's pivastatin calcium tablets and other stock market share and sales scale is relatively large.
from the list of the high market share of the stock of enterprises, Hengrui has 4 over-rated varieties market share is high, respectively, Capeta bin tablets, recoctalic tablets, non-busta tablets and hydrochloric acid ammonia bromine tablets, 2020Q1 sales market share Sample hospital sales reached 1.240 billion yuan, 728 million yuan, 522 million yuan and 18.957 million yuan in 2019, respectively.
Revival Medicine has three varieties, including non-bustatine tablets, pistatin calcium tablets and fumatox-pyridine tablets, with 2020Q1 sales accounting for 37.1%, 27.85% and 21.9%, respectively, and 2019 sample hospital sales reaching 522 million yuan, 360 million yuan and 223 million yuan, respectively.
in addition, Beijing new drug industry's hydrochloric acid Shequlinping, Shanghai Pharma's hydrochloric acid metformin slow release tablets, Tianshi li and Kanghong Pharmaceutical's right Zopiquelon tablets, China Biopharmaceuticals hydrochloric acid amino glucose tablets, Enhua Pharmaceuticals chlorine nitrogen flat tablets, Xinlitai's ground chloratorine tabletmarket is also relatively high.
, the market share of the right Zopiclon film is almost divided by Tianshi Li and Kanghong Pharmaceuticals.
Tianshili's right Zopiquelon 2020Q1 sales accounted for 64.1%, Kanghong Pharmaceutical Market accounted for 33.4%, in 2019 the product in the sample hospital sales of 866.45 billion yuan.
China Biopharmaceuticals amino glucose tablets 2020Q1 sales accounted for 52.6%, accounting for more than half.
2019 sales of the species in the sample hospital were 84.552 million yuan.
Enhua Pharmaceuticals' chlorine-nitrogen flat 2020Q1 sales accounted for 36.5%, and in 2019 the product's sales in the sample hospital were 12.266 million yuan.
in addition, had no chance of "two batches of collection" of metformin this time into the collection list, has been highly concerned by the industry.
the variety of domestic generic drug production enterprises, foreign-funded pharmaceutical enterprises accounted for a larger proportion, so the market competition is very fierce.
the current variety has passed the drug consistency evaluation of the production of pharmaceutical companies as many as dozens.
from the market share of the product, Shanghai Pharma's acetate 2020Q1 sales accounted for 10.7%.
due to the number of pharmaceutical finalists of the same variety of no more than eight, industry insiders predict that in this collection, the production of metformin pharmaceutical companies will face fierce competition, is expected to be higher price reduction.
it is well known that the purpose of carrying out the volume procurement is to squeeze out the water of the inflated drug price, and realize imitation substitution of the original research.
these original high market share of the varieties of sales once the winning bid, the relevant enterprises will further expand the market share, conducive to accelerating the realization of generic substitution.
and for some of the original market share of the low-yield varieties, once the winning bid, the relevant "barefoot enterprises" can also improve profitability and improve cash flow.
but the industry believes that it is also necessary to see that in the health insurance balance policy and the state, local collection of complementary circumstances, if the relevant companies do not win the bid, it means that enterprises will gradually lose the stock of large varieties of market space.
.